Grey Wolf is a UK and Australian-based drug discovery and development company focused on developing novel immuno-oncology agents. The company was founded in 2017 by experienced industry professionals; Tom McCarthy (Executive Chairman; former President and CEO of Spinifex Pharmaceuticals), and Peter Joyce (CEO; former Project Leader at Vertex Pharmaceuticals).
Rather than targeting the immune system, Grey Wolf’s approach is to directly alter tumour cells, illuminating them for attack and destruction by the immune system. The company is developing small molecules that inhibit the endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2), which play a key role in the antigen presentation pathway. Grey Wolf has demonstrated that inhibiting these enzymes leads to modulation of the antigen repertoire within tumour cells, dramatically increasing tumour visibility and extending the reach of immunotherapy in oncology. Grey Wolf’s unique therapeutic strategy is centred on generating a novel immune response against tumours that circumvents key resistance mechanisms to current immuno-oncology therapy, namely poor tumour recognition by T cells and T cell exhaustion.
Grey Wolf is working with leading academic and commercial drug discovery and development partners to deliver first-in-class clinical candidates against these strongly validated targets. The core team is strengthened by a network of collaborations with experts in immuno-oncology, antigen presentation and drug discovery across world leading academic institutions, including The University of Oxford, Monash University, and University of Southampton.
Grey Wolf is executing on multiple programs that are all focused on harnessing the potential of targeting ERAP as a differentiated and innovative approach to modulate tumour visibility in immuno-oncology.
Grey Wolf is a private company supported by investors committed to delivering next generation oncology therapies.
Collaboration is at the heart of everything we do. We create a safe environment for constructive, productive and passionate conversations to take place around issues that are important. We encourage everyone to contribute positively.
We continuously seek new ideas and innovative ways to ensure we are world leading in all areas. We go deep into any challenge so that we are comfortable taking risks.
We strive to be the best in everything we do. We set high standards ensuring we deliver against agreed outcomes. We think things through thoroughly and are pragmatic in our approach to implement ideas and methodology based on all available information.
We make decisions quickly after considering the options. We execute on our decisions and actions to keep moving forward. We make every day count.